English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
Monday, 6th January at 9:00 am
NeuroSense in Compliance with all Nasdaq Listing Requirements
CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's stockholders' equity requirement ("Equity Requirement") set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Ordinary Shares will continue to be listed and trade on The Nasdaq Capital Market under the symbol "NRSN".
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
1585 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8031
    Followers
    50
    Following
    91K
    Visitors
    Follow
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.